Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene Therapy for beta-thalassemia.

Punam Malik1, Paritha I Arumugam

  • 1Children's Hospital Los Angeles, 4650 Sunset Blvd., M.S. #45, Los Angeles, CA 90027, USA. pmalik@chla.usc.edu

Hematology. American Society of Hematology. Education Program
|November 24, 2005
PubMed
Summary

Lentiviral (LV) vectors offer a promising gene therapy for beta-thalassemia, a blood disorder. Insulated self-inactivating LV vectors achieve stable, therapeutic beta-globin expression, correcting the disease in patient cells and mice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in Sickle Cell Disease.

Blood·2026
Same author

Cure Sickle Cell Initiative recommendations on common data elements for sickle cell disease gene therapy trials.

Blood advances·2026
Same author

Angiotensin signaling is essential for stress erythropoiesis but causes retention of dysfunctional mitochondria in RBCs.

JCI insight·2026
Same author

Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview.

American journal of hematology·2026
Same author

Longitudinal changes and predictors of cardiac extracellular volume fraction in sickle cell anemia.

Blood. Red cells & iron·2025
Same author

Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial.

Nature medicine·2025

Area of Science:

  • Hematology
  • Gene Therapy
  • Molecular Biology

Background:

  • Beta-thalassemia treatment requires effective gene transfer into hematopoietic stem cells.
  • Previous oncoretroviral vectors faced challenges with stability, low titers, and inconsistent gene expression.
  • Human immunodeficiency virus-based lentiviral (LV) vectors show potential for stable gene transmission.

Purpose of the Study:

  • To evaluate the efficacy of lentiviral vectors for treating beta-thalassemia.
  • To improve the stability and expression levels of beta-globin gene transfer.
  • To assess the safety and long-term correction of beta-thalassemia using advanced LV vectors.

Main Methods:

  • Utilized self-inactivating (SIN) lentiviral vectors incorporating the beta-globin gene and locus control region.

Related Experiment Videos

  • Integrated the chicken hypersensitive site-4 (cHS4) insulator element into SIN-LV vectors.
  • Tested vector efficacy in mouse models and patient-derived cells, including in vivo xeno-transplantation studies.

    • Main Results:

    • Insulated SIN-LV vectors demonstrated stable and enhanced human beta-globin expression compared to non-insulated vectors.
    • Achieved phenotypic correction of beta-thalassemia in patient-derived cells in vitro.
    • Demonstrated long-term correction in xeno-transplanted mice, indicating sustained therapeutic effect.

    Conclusions:

    • Lentiviral vectors, particularly insulated SIN-LV vectors, represent a viable strategy for clinical gene therapy trials in beta-thalassemia.
    • These vectors offer improved safety profiles by reducing viral transcriptional elements and enhancing lineage restriction.
    • Further optimization with chromatin insulators may enhance the safety and efficacy of gene therapy for beta-globin disorders.